Tuesday , November 21 2017
Home / Therapies / GLP-1 Agonist Therapy Center (page 8)

GLP-1 Agonist Therapy Center

GLP-1 Diabetes Drug Treatment: GLP-1 (glucagon-like peptide 1 receptor agonists) are incretin mimetics which have several benefits for diabetes management. They suppress post-prandial glucagon release, delay stomach emptying, and increase insulin sensitivity. Significantly lower rates of hypoglycemia accompany GLP-1 therapy. This class also has the side effect of modest weight reduction and reduction of systolic blood pressure. GLP-1 receptor agonists are counter-indicated for patients with a history of pancreatitis.

GLP-1 Agonist Medications Chart

This chart outlines the latest medications approved by the FDA for diabetes treatment and the differences and similarities between them. Print out this chart and post in your office as a handy reference for your staff and patients alike…. To download this in PDF format, just use this link: GLP-1 Agonist Medications …

Read More »

ADA 2014 – GLP-1 Update

For this month’s special feature we have a selection of the GLP-1 abstracts and releases from the recent American Diabetes Association’s 74th Scientific Sessions in San Francisco. New one-year data of IDegLira shows glucose-lowering effect was maintained for people with type 2 diabetes New Phase 3a findings show IDegLira, the …

Read More »